ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Panel May Take On OMB In Battle to Restore NCI Construction Funds; Two Will Be Funded In FY ‘83

November 12, 1982

Reinventing NCI: Rimer Says Report Consistent with Her Goals For DCCPS

October 17, 1997

DeVita Suggest Chop Should Be Expanded, Given Long Term Status, But Only With A “Quid Pro Quo”

March 20, 1981

FDA, Clinical Investigators Head Or Showdown Over Demand To See Individual Patient Records

April 18, 1980

In Brief: Christopher Walsh Named Dana-Farber President; Sachs Leaves NCI; Acoustic Neuroma Conference

August 16, 1991

DCT Board Approves Recompetition Of Drug Development Contracts

June 25, 1993